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Month of birth, vitamin D and risk of immune-
mediated disease: a case control study
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Abstract
Background: A season of birth effect in immune-mediated diseases (ID) such as multiple sclerosis and type 1
diabetes has been consistently reported. We aimed to investigate whether season of birth influences the risk of
rheumatoid arthritis, Crohn’s disease, ulcerative colitis and systemic lupus erythematosus in addition to multiple
sclerosis, and to explore the correlation between the risk of ID and predicted ultraviolet B (UVB) light exposure and
vitamin D status during gestation.
Methods: The monthly distribution of births of patients with ID from the UK (n = 115,172) was compared to that
of the general population using the Cosinor test. Predicted UVB radiation and vitamin D status in different time
windows during pregnancy were calculated for each month of birth and correlated with risk of ID using the
Spearman’s correlation coefficient.
Results: The distributions of ID births significantly differed from that of the general population (P = 5e-12) with a
peak in April (odds ratio = 1.045, 95% confidence interval = 1.024, 1.067, P < 0.0001) and a trough in October
(odds ratio = 0.945, 95% confidence interval = 0.925, 0.966, P < 0.0001). Stratification by disease subtype showed
seasonality in all ID but Crohn’s disease. The risk of ID was inversely correlated with predicted second trimester
UVB exposure (Spearman’s rho = -0.49, P = 0.00005) and third trimester vitamin D status (Spearman’s rho = -0.44,
P = 0.0003).
Conclusions: The risk of different ID in the UK is significantly influenced by the season of birth, suggesting the
presence of a shared seasonal risk factor or factors predisposing to ID. Gestational UVB and vitamin D exposure
may be implicated in the aetiology of ID.
Background
Complex disorders such as immune-mediated diseases
(ID) are defined as conditions that have no single cause
but result from a combination of genetic and environ-
mental factors and their interactions. ID affect approxi-
mately 5% to 10% of the developed world and the overall
incidence seems to be increasing [1]. This observation
suggests that changes in environment and lifestyle play a
central role in influencing prevalence.
Seasonality dominates the global environment and diet
is closely related to seasonality by the effect of these
environmental fluctuations on agriculture [2]. Seasonal
factors can potentially act even before birth, when,
according to the ‘fetal origin of adult disease hypothesis’,
environmental influences leading to changes in embryo-
nic or fetal tissue structure and function can influence
the risk of adult physiological and pathological condi-
tions [3,4]. As a consequence, being born at a certain
time of the year may influence susceptibility to disease
later in life. Indeed, month of birth effects have already
been documented in ID such as multiple sclerosis (MS)
and type 1 diabetes (T1D) [5-7]. In addition to MS and
T1D, a few other studies have investigated the presence
of a month of birth effect in other ID. However, poor
sample sizes and inadequate statistical methods have
significantly hampered these attempts and results are
inconsistent [8-16].
The mechanisms involved in the pathogenesis of ID
are variable, and both adaptive and innate immune
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responses have been implicated in diseases such as MS,
rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), Crohn’s disease (CD) and ulcerative colitis (UC)
[17-20]. For example, in MS and RA tolerance break-
down is thought to cause immune-mediated demyelina-
tion of the central nervous system and cartilage and
bone destruction respectively [18,21]. By contrast, sev-
eral lines of evidence suggest that CD and UC arise
from an inappropriate immune reaction to the intestinal
microbiota in genetically predisposed hosts [20]. Despite
these differences, an abnormal activation of the immune
system is a common thread linking these conditions and
several observations indicate that similar genetic path-
ways and environmental agents, such as vitamin D defi-
ciency, smoking behaviour and various infections, are
involved in the pathogenesis of these disorders
[18-20,22-25].
This led us to the a priori hypothesis that a similar
seasonality of birth may be present among different ID.
We investigated whether the month of birth influences
susceptibility to RA, SLE, CD and UC in addition to MS
using the largest cohort to date to investigate these
effects (n = 115,172). Since all these conditions have
been linked to vitamin D deficiency [23,24], we also
tested whether the risk of disease by month of birth fol-
lows the same seasonal distribution of predicted ultra-
violet B (UVB) light radiation and 25-hydroxyvitamin D
(25-OH-D) levels during gestation.
Methods
Month of birth for MS (n = 15,492), RA (n = 39,666),
SLE (n = 4,046), CD (n = 20,574) and UC (n = 23,892)
patients seen by a doctor between 1997 and 2009 in Scot-
land and between 2003 and 2009 in England were
obtained from the National Health Service (NHS) Scot-
land and the English Hospital Episode Statistics (HES).
For MS, an additional cohort of patients (n = 11,502) and
matched controls was collected as previously described
[5], giving a total of 26,994 MS patients. General popula-
tion controls were obtained from the General Register
Office http://www.gro-scotland.gov.uk/ and the Office
for National Statistics http://www.ons.gov.uk/. Scottish
controls were based on month of birth registration
between 1954 and 1973 and actual month of birth
between 1974 and 1990. English controls were based on
actual month of birth between 1950 and 1990. In total,
month of birth data were collected for 115,172 patients
with ID (26,162 English and 89,010 Scottish, Table 1) as
well as for 3,028,621 Scottish and 29,202,890 English
controls.
We compared cases and controls using the Cosinor test,
which is able to capture seasonal distributions and is parti-
cularly suitable for relatively simple and symmetric seaso-
nal patterns. This test fits a generalized linear model
under the Poisson distribution using sine and cosine terms
that together describe the sinusoid. In addition to statisti-
cal significance, the model provides information on the
amplitude (the height) and the phase (the peak point from
1 to 12 indicating months) of the predicted sinusoid [26].
Monthly odds ratios (OR) were also calculated by compar-
ing frequencies of patients and controls born in a certain
month versus the rest of the year.
Average monthly UVB radiation at the wavelength of
305 nm at noon (joules/square metre) in England and
Scotland between 1979 and 1992 was obtained from the
National Aeronautics and Space Administration’s Total
Ozone Mapping Program on the Nimbus 7 satellite, as
previously described [27]. Average monthly 25-OH-D
levels were collected from a large cohort of adult Scottish
and English women (n = 3,787) as previously described
[28] and used as a proxy for the seasonal variation in
gestational vitamin D status. Average predicted UVB expo-
sure as well as vitamin D status during the first, second
and third trimesters of gestation were calculated for each
month of birth and tested for correlation with risk of ID
(monthly OR) using the Spearman’s correlation coefficient.
Statistical analyses were performed using R.
Results
To assess whether month of birth influences susceptibility
to immune disorders, we initially compared the distribu-
tion of all patients with ID with that of the general popula-
tion. Using the Cosinor test, the birth distribution of
patients with ID was found to follow a seasonal distribu-
tion as compared with the general population (P = 5e-12,
amplitude = 0.033, phase = 3.08, low point = 9.08). When
monthly ORs were calculated, a statistically significant
peak was found in April (OR = 1.045, 95%CI = 1.024 to
1.067, P < 0.0001) and a significant trough exactly six
months later in October (OR = 0.945, 95%CI = 0.925 to
0.966, P < 0.0001). A smaller deficit was also detected in
August (OR = 0.972, 95%CI = 0.951 to 0.9927, P = 0.008)
Table 1 Total number of patients with immune-mediated diseases used in the analysis
Multiple
sclerosis
Rheumatoid
arthritis
Systemic lupus
erythematosus
Crohn’s
disease
Ulcerative
colitis
All immune-mediated
diseases
England 13,075 4,747 1,622 2,463 4,255 26,162
Scotland 13,919 34,919 2,424 18,111 19,637 89,010
Total 26,994 39,666 4,046 20,574 23,892 115,172
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(Figure 1). The peak to trough ratio indicated the presence
of a 6.5% increased risk for individuals born in April ver-
sus those born in October (OR = 1.065, 95%CI = 1.035 to
1.096, P < 0.0001).
When the analysis was performed according to coun-
try, the seasonal effect appeared to be present in both
England and Scotland (Scotland P = 5e-10, amplitude =
0.034, phase = 3.05, low point = 9.05; England P =
0.005, amplitude = 0.032, phase = 3.23, low point =
9.23). The highest and lowest monthly ORs were found
in the Scottish population; however, 95%CIs were sub-
stantially overlapping (Figure 2).
The seasonality of birth detected by grouping all
patients with ID could arise from a single disease such as
MS, for which the presence of a month of birth effect has
already been described. We therefore stratified the analy-
sis by disease type. The Cosinor test indicated the pre-
sence of clear seasonality in all ID but CD: MS, P = 5e-06;
amplitude = 0.041, phase = 4.12, low point = 10.12; RA,
P = 5e-04, amplitude = 0.032, phase = 2.69, low point =
8.69; UC, P = 5e-04, amplitude = 0.04, phase = 2.74, low
point = 8.74; SLE, P = 0.025, amplitude = 0.063, phase =
2.89, low point = 8.89; CD, P > 0.05. When calculating
monthly ORs, a peak in spring and a deficit in autumn
could be observed in each ID apart from CD, in which a
January rather than spring peak was found. Birth percen-
tages and monthly ORs with 95%CIs are presented in
Table 2.
We next investigated whether the monthly risk of ID
inversely correlated with predicted gestational UVB
exposure and vitamin D status during different trime-
sters of pregnancy. Based on the Nimbus 7 satellite,
UVB radiation in the UK reaches the minimum and
maximum levels during winter (December to January)
and summer (June to July), respectively. The highest
and lowest 25-OH-D levels were collected during
September and February respectively [28]. Figure 3
shows the direct relation between UVB radiation and
vitamin D status and the amount of time required for a
change in UVB to impact on vitamin D metabolism.
The peak and the trough of 25-OH-D levels are shifted
approximately two to three months later than UVB
radiation (two months lag: Spearman’s rho = 0.91, P <
2.2e-16; three months lag: Spearman’s rho = 0.88, P =
0.002). This is consistent with previous reports [29].
We found that the monthly risk of ID inversely corre-
lated with predicted UVB exposure during the second
trimester of pregnancy (Spearman’s rho = -0.49, P =
0.00005). Similarly, predicted maternal 25-OH-D levels
were also inversely associated with risk of ID but the
negative correlation was shifted to the third trimester
(Spearman’s rho = -0.44, P = 0.0003) (Figure 4).
Discussion
We report here the largest study performed on ID and
seasonality of birth. When patients with different condi-
tions were grouped together, a clear seasonal birth distri-
bution was observed with a peak in April and a trough
exactly six months later in October. The effect size of
being born at the ‘wrong time’ appears very low, with the
highest ORs being under 1.1. However, considering the
increased risk of all ID in the rest of the year versus
October-born individuals and the proportion of the
population born in months other than October, the
population proportional attributable risk per cent is
5.05%. This suggests that approximately 5% of ID cases
could be prevented by ameliorating the risk factor
responsible for the seasonal distribution of ID births. The
season of birth effect was particularly clear in Scotland as
compared with England, but no prominent differences
between the two sites could be observed.
That the risk of MS varies by month of birth has
already been shown in a number of regions, including
Figure 1 Odds ratio distribution with 95% CI based on month
of birth in all immune-mediated diseases (n = 115,172) versus
general population. April peak and October trough of risk can be
observed.
Figure 2 Odds ratio distribution based on month of birth in
England and Scotland. The highest and lowest odds ratios are
observed in Scotland but 95%CI substantially overlap.
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Canada, Denmark, Sweden, Sardinia, Finland, England,
Scotland and Australia [5,30-34]. We further confirmed
these findings by increasing the sample size of a pre-
viously analysed cohort of UK patients with MS [5].
Based on the Cosinor test, RA, UC and SLE births also
followed a clear seasonal distribution. Notably, all the
predicted sinusoids peaked around the same period,
with phases ranging from 2.69 to 4.12 (late winter-
spring). In contrast to other ID, the distribution of CD
births was not seasonal.
The presence of seasonality of births among patients
with UC but not CD is interesting but difficult to interpret.
Somehow similar is the observation that the season of
birth effect in MS is present among patients with relapsing
remitting but not primary progressive MS [35]. It is there-
fore plausible to observe such differences between similar
but distinct phenotypes. Furthermore, increasing evidence
supports the presence of gene-environment interactions in
disease aetiology [36,37] and particular genetic variants
could be involved and mediating the season of birth effect.
Although many genetic variants influence the risk of both
UC and CD, many others (including variants located
within the major histocompatibility complex) appear to be
disease specific and this could contribute to the observed
difference between UC and CD births [20,38-41].
A recent Australian study reported an inverse associa-
tion between the risk of MS and UVB exposure during
Table 2 Birth percentages and monthly odds ratios with 95%CI for each and all immune-mediated diseases
Month All immune-mediated diseases Multiple sclerosis Rheumatoid arthritis
Birth % OR 95% CI Birth % OR 95% CI Birth % OR 95% CI
Jan 8.63 1.02 + 0.99 to 1.04 8.51 1.01 0.97 to 1.05 8.44 0.99 0.95 to 1.03
Feb 7.90 1.01 0.99 to 1.04 7.76 0.99 0.95 to 1.03 7.94 1.02 0.98 to 1.06
Mar 8.88 1.00 0.98 to 1.02 8.67 0.97 0.93 to 1.01 8.99 1.01 0.98 to 1.05
Apr 8.77 1.05 + 1.02 to 1.07 8.79 1.05 + 1.002 to 1.09 8.78 1.05 + 1.01 to 1.08
May 8.83 1.01 0.99 to 1.03 9.41 1.08 + 1.04 to 1.13 8.64 0.99 0.95 to 1.03
Jun 8.44 1.01 0.99 to 1.04 8.70 1.04 1.01 to 1.09 8.47 1.02 0.98 to 1.06
Jul 8.49 0.99 0.97 to 1.01 8.51 0.99 0.95 to 1.04 8.37 0.98 0.94 to 1.01
Aug 8.16 0.97 - 0.95 to 0.99 8.20 0.98 0.94 to 1.02 8.14 0.97 - 0.93 to 1.00
Sep 8.12 1.00 0.97 to 1.02 7.94 0.96 0.92 to 1.01 8.10 1.00 0.96 to 1.03
Oct 8.05 0.95 - 0.92 to 0.97 8.08 0.96 - 0.92 to 1.00 8.20 0.96 - 0.93 to 0.99
Nov 7.61 0.98 0.96 to 1.00 7.43 0.96 - 0.91 to 1.00 7.65 0.99 0.95 to 1.02
Dec 8.11 1.01 0.99 to 1.03 8.01 1.00 0.96 to 1.04 8.30 1.04 + 1.00 to 1.07
Month Ulcerative colitis Systemic lupus erythematosus Crohn’s disease
Birth % OR 95% CI Birth % OR 95% CI Birth % OR 95% CI
Jan 8.63 1.02 0.97 to 1.06 9.57 1.14 + 1.03 to 1.27 8.99 1.06 + 1.01 to 1.11
Feb 8.07 1.04 + 0.99 to 1.09 7.86 1.00 0.90 to 1.13 7.84 1.01 0.96 to 1.06
Mar 8.90 1.00 0.96 to 1.05 8.75 0.98 0.88 to 1.09 8.94 1.01 0.96 to 1.06
Apr 8.92 1.06 + 1.02 to 1.11 8.85 1.05 0.95 to 1.18 8.54 1.02 0.97 to 1.07
May 8.73 1.00 0.96 to 1.05 9.71 1.12 + 1.01 to 1.24 8.40 0.96 - 0.91 to 1.01
Jun 8.25 0.99 0.94 to 1.04 7.61 0.90 0.81 to 1.02 8.44 1.02 0.97 to 1.07
Jul 8.44 0.99 0.94 to 1.03 8.58 1.00 0.90 to 1.12 8.75 1.03 0.98 to 1.08
Aug 8.15 0.97 - 0.93 to 1.02 8.40 1.00 0.90 to 1.12 8.13 0.97 0.92 to 1.02
Sep 8.18 1.00 0.96 to 1.05 7.51 0.91 - 0.81 to 1.02 8.45 1.04 + 0.99 to 1.10
Oct 7.91 0.93 - 0.88 to 0.97 7.93 0.94 0.84 to 1.05 7.89 0.92 - 0.87 to 0.97
Nov 7.69 0.99 0.95 to 1.04 7.09 0.91 - 0.81 to 1.03 7.78 1.00 0.95 to 1.06
Dec 8.13 1.01 0.97 to 1.06 8.13 1.02 0.91 to 1.14 7.84 0.97 0.93 to 1.03
+ and - indicate highest and lowest odds ratios, respectively. CI: confidence intervals; OR: odds ratio.
Figure 3 Correlation between monthly ultraviolet B radiation from
the NASA’s Total Ozone Mapping Program and 25-
hydroxyvitamin D levels from the general UK population. The
seasonal distribution of 25-hydroxyvitamin D levels is shifted
approximately two to three months later than that of ultraviolet B
radiation.
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the first trimester of gestation [31]. However, the sample
size was relatively small (n = 1,524) and thus analysis
had to be performed using bi-monthly periods. Further-
more, the seasonal variation of 25-OH-D levels was not
investigated and no other studies have tried to answer
the same question in ID other than MS. We found that
the risk of ID was inversely associated with predicted
second trimester UVB exposure and third trimester vita-
min D status. These findings are interesting since sev-
eral lines of evidence now support a role for vitamin D
deficiency in the pathogenesis of ID [23,24]. Notably,
vitamin D production is strictly dependent on UVB
radiation and vitamin D levels therefore follow a seaso-
nal distribution [23]. This is also the case among preg-
nant women, whose vitamin D status largely depends on
season and follows the same distribution as the levels of
the general population [28,42,43]. Furthermore, in utero
vitamin D deficiency has a significant effect on the
developing immune system and our group has recently
shown that genes associated with MS, RA, CD, SLE and
T1D are significantly enriched for vitamin D receptor
binding sites [44-46]. In addition to its well-known
immunological roles, this exceptionally pleiotropic hor-
mone has been implicated in autophagy and mucosal
barrier homeostasis, which are thought to play a patho-
genic role in CD and UC [20,47,48]. It may be that in
utero vitamin D deficiency, in conjunction with indivi-
dual genetic variation and subsequent exposure to other
environmental agents, may then lead to disease specifi-
city. Notably, schizophrenia is also influenced by the
season of birth and a recent study has shown that neo-
natal vitamin D levels are significantly associated with
risk of schizophrenia later in life [49,50]. Future studies
should try to answer the same question in MS as well as
in other ID.
This study has limitations. Information on sex and eth-
nicity was not available and this may have confounded our
results. Furthermore, the data we gathered from the Scot-
tish NHS and the English HES could not be restricted to
UK born but only to UK resident individuals. However,
the enormous sample size (115,172 ID cases), the relatively
homogeneous Scottish population and the strong a priori
evidence for a month of birth effect in MS make the risk
of a spurious association improbable. Furthermore, it is
striking that the ID analysed (apart from CD) show a simi-
lar seasonal risk distribution, which is also the one
reported in patients with T1D [6,7]. This makes the data
unlikely to be a chance finding.
We were limited to using average UVB radiation and
general population vitamin D measures, which may dif-
fer from the individual maternal exposures. It is impor-
tant to note that our UVB and vitamin D correlation
analysis does not prove causation and that, although the
vitamin D hypothesis is supported by both epidemiologi-
cal and functional observations, seasonality dominates
many features of the global environment and other sea-
sonal factors may play a role in determining the risk of
ID. Climate, temperature, infectious disease and mater-
nal nutrition are all characterised by seasonality and
thus represent excellent candidate factors.
Conclusions
The susceptibility to different ID in the UK is influenced
by the season of birth. This is particularly clear in
patients with MS, RA, UC and SLE and suggests that at
least some proportion of ID risk is preventable. Gesta-
tional vitamin D deficiency appears to be a plausible
causative agent. The identification of the seasonal factor
or factors responsible for such observations will be cru-
cial for disease prevention strategies.
Figure 4 Inverse correlation between risk of immune-mediated diseases and predicted second trimester ultraviolet B exposure (left
panel) and third trimester vitamin D status (right panel).
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